|
A Study of Methylprednisolone in People Having Liver Surgery
RECRUITINGPhase 3Sponsored by Memorial Sloan Kettering Cancer Center
Actively Recruiting
PhasePhase 3
SponsorMemorial Sloan Kettering Cancer Center
Started2026-03-27
Est. completion2029-03-27
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations19 sites
View on ClinicalTrials.gov →
NCT07507643
Summary
The purpose of this study is to test whether receiving methylprednisolone before surgery will reduce the side effects of having surgery, such as infections and longer hospital stays.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Age ≥18 years at the time of consent. * Scheduled to undergo elective major hepatectomy (defined by CPT codes 47122 \[trisegmentectomy\], 47125 \[total left hepatectomy\], or 47130 \[total right hepatectomy\]). * In addition to major hepatectomy, as defined above, patients may undergo additional partial hepatectomy or operative ablation. Exclusion Criteria: * Known or documented adverse reactions to methylprednisolone. * Unable to receive methylprednisolone because of coexisting medical conditions. * Long-term (≥10-day course) systemic corticosteroid use, regardless of dose, if doses have been administered within 30 days of the planned date of surgery. This will not apply to steroids administered, in accordance with the standard of care, with preoperative chemotherapy. The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive-airway diseases), eye drops, and local injections (e.g., intra-articular). * Significant chance (based on surgeon judgement) of being unable to successfully complete surgery because of unresectability. * Expected or highly likely to undergo concomitant major organ resection (stomach, pancreas, colon, rectum, uterus, ovaries, bladder, kidney, small bowel). * Expected or highly likely to undergo biliary tree reconstruction via creation of a biliary-enteric anastomosis. * Scheduled to undergo concurrent insertion of a hepatic artery infusion pump device. * Estimated renal dysfunction defined by any of the following: creatinine clearance ≤40 mL/min as calculated by the Cockcroft-Gault Equation, currently on hemodialysis, currently on peritoneal dialysis. * Dependence on mechanical ventilation before surgery. * Pregnant or nursing (lactating), where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test. * Known at the time of enrollment to have a bacterial infection that is expected to be present at the time of surgery or receipt of systemic antibiotic or antifungal therapy within 7 days before surgery. * Unable to provide informed consent
Conditions3
CancerHepatectomyLiver Cancer
Interventions1
Locations19 sites
Rush University Medical Center (Data collection only)
Chicago, Illinois, 606012
Matt Dixon, MD312-738-3732
University of Chicago (Data Collection Only)
Chicago, Illinois, 60637
Ryan Merkow, MD773-702-1470
Indiana University (Data Collection Only)
Indianapolis, Indiana, 46202
Ryan Ellis, MD317-944-0920
UNIVERSITY OF IOWA (Data Collection Only)
Iowa City, Iowa, 52242
Carlos Chan, MD319-356-1727
University of Kentucky (Data Collection Only)
Lexington, Kentucky, 40536-0093
Michael Cavnar, PhD859-257-9612
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorMemorial Sloan Kettering Cancer Center
Started2026-03-27
Est. completion2029-03-27
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations19 sites
View on ClinicalTrials.gov →
NCT07507643